Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 10/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 9/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 7/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5416535 | 0.99 | HTR7 (0.45) | HTR7ADRA1AADRA1BADRA1DHTR1A | |
| SCHEMBL5416585 | 0.92 | ADRA1A (0.42) | HTR7ADRA1AADRA1BADRA1DHTR1A | |
| SCHEMBL5424838 | 0.91 | HTR7 (0.42) | HTR7ADRA1AADRA1BADRA1DHTR1A | |
| Hydrochloric Acid SCHEMBL5423794 | 0.91 | ADRA1A (0.41) | HTR7ADRA1AADRA1BADRA1DHTR1A | |
| SCHEMBL5428352 | 0.91 | ADRA1A (0.42) | HTR7ADRA1AADRA1BADRA1DHTR1A | |
| Hydrochloric Acid SCHEMBL5424328 | 0.90 | HTR7 (0.41) | HTR7ADRA1AADRA1BADRA1DHTR1A | |
| Hydrochloric Acid SCHEMBL5426783 | 0.90 | ADRA1A (0.42) | HTR7ADRA1AADRA1BADRA1DHTR1A | |
| SCHEMBL5423890 | 0.89 | ADRA1A (0.41) | HTR7ADRA1AADRA1BADRA1DHTR1A | |
| SCHEMBL5427895 | 0.89 | HTR1A (0.46) | HTR7ADRA1AADRA1BADRA1DHTR1A | |
| SCHEMBL5426005 | 0.89 | ADRA1A (0.44) | ADRA1AADRA1BADRA1DHTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219216-A1 | 1-Alkylpiperazinyl-Pyrrolidin-2,5-Dione Derivatives as Adrenergic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-09-20 | — | — | US | claimed |
| US-20070219216-A1 | 1-Alkylpiperazinyl-Pyrrolidin-2,5-Dione Derivatives as Adrenergic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219216-A1 | 1-Alkylpiperazinyl-Pyrrolidin-2,5-Dione Derivatives as Adrenergic Receptor Antagonists | ADRA1D, ADRA1A, ADRB1 | HTR7 382/4885ADRA1A 2/4885ADRA1B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.